CJC-1295 Questions, Answered: A Research Reference

This page consolidates the most frequently asked questions about CJC-1295 into a single reference, answering each one from published peer-reviewed research, manufacturer documentation, and regulatory records. CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analogue supplied strictly as a research use only chemical, and everything below is written for laboratory and literature-review contexts rather than personal use. Where the published evidence is thin or absent, that is stated plainly instead of filled in with speculation.

What CJC-1295 actually is, and what it is not

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, not growth hormone itself and not a steroid. Its core is a modified fragment of endogenous GHRH — the first 29 amino acids, the same active region used by sermorelin — with four amino acid substitutions that resist enzymatic degradation by dipeptidyl peptidase-4. Because it is a peptide built from amino acids, it bears no structural resemblance to the four-ring steroid nucleus shared by testosterone, nandrolone, and other anabolic-androgenic steroids.

The functional distinction matters more than the chemical one. Anabolic steroids bind intracellular androgen receptors and directly drive gene transcription in muscle and other tissues, producing effects that continue regardless of what the pituitary is doing. CJC-1295 does not bind androgen receptors at all. It binds GHRH receptors on somatotroph cells in the anterior pituitary and asks that gland to release its own stored growth hormone. The output is therefore bounded by the pituitary's capacity and by normal negative feedback from somatostatin and circulating IGF-1.

The same logic separates CJC-1295 from exogenous recombinant human growth hormone. Injected rhGH floods the circulation with a fixed, non-physiological quantity of hormone and suppresses the body's own GHRH-driven pulses. A GHRH analogue works upstream, amplifying the amplitude of pulses the organism already generates. Research literature consistently describes this as a more physiologic pattern, though it also means the effect size depends entirely on whether the pituitary reserve is intact.

Confusion between these categories is understandable. CJC-1295 appears in the same forums, supplier catalogs, and anti-doping code sections as steroids and rhGH, and all three are discussed in connection with body composition. But grouping them together obscures a genuine mechanistic difference: one class replaces a hormone, another mimics a hormone, and CJC-1295 signals a gland to produce more of its own.

What research reports about the mechanism of action

CJC-1295 works by binding the GHRH receptor, a G-protein-coupled receptor on pituitary somatotrophs, triggering cAMP accumulation and calcium influx that culminates in growth hormone exocytosis. Released GH then acts on hepatic and peripheral GH receptors, and the liver responds by producing insulin-like growth factor 1 (IGF-1), which mediates a large share of GH's downstream anabolic and metabolic signaling.

Two features explain why this molecule persisted where earlier GHRH fragments failed. First, the four substitutions in the peptide backbone block DPP-4 cleavage, which otherwise inactivates native GHRH within a couple of minutes. Second, the version described in the literature as CJC-1295 with DAC carries a Drug Affinity Complex — a maleimidoproprionic acid group that forms a covalent bond with cysteine-34 on circulating serum albumin. Albumin has a half-life measured in weeks, so the tethered peptide is shielded from renal clearance and enzymatic breakdown and is released gradually into circulation.

Published pharmacokinetic work in healthy adults reported a terminal half-life for the DAC-bearing form in the range of roughly six to eight days, with measurable elevations in growth hormone and IGF-1 persisting for many days after a single dose. That is the source of the widely cited claim that CJC-1295 with DAC produces sustained GH elevation — it does, but the elevation is best characterized as a raised baseline or "bleed" rather than a series of sharper pulses.

What research reports about the DAC and non-DAC forms

The single difference between the two forms is the albumin-binding Drug Affinity Complex, and it changes the pharmacokinetic profile completely. Without DAC — the molecule more accurately named modified GRF (1-29), though catalogs routinely label it CJC-1295 no-DAC — the peptide retains DPP-4 resistance but clears quickly, with a half-life commonly reported at around thirty minutes. It produces a discrete GH pulse that rises and falls within a couple of hours.

With DAC, the peptide remains in circulation for days and produces a prolonged, comparatively flat elevation in GH and IGF-1. Each profile suits different research questions:

• Short-acting form: preferred in protocols where temporal precision matters — acute GH release studies, pulse-amplitude measurement, experiments designed to preserve the natural nocturnal GH rhythm, or work pairing a GHRH analogue with a secretagogue to study synergy at a defined time point.
• DAC form: used where the research question concerns chronic exposure — long-run IGF-1 kinetics, bone turnover markers, or study designs where infrequent administration reduces handling stress in animal models.

A recurring theme in the physiology literature is that endogenous GH secretion is pulsatile for a reason. Receptor sensitivity, hepatic IGF-1 transcription patterns, and the interplay with somatostatin all appear tuned to episodic signaling, and continuous exposure can attenuate responsiveness over time. This is why many investigators treat the constant elevation from the DAC form as a distinct pharmacological state rather than simply "more" of what the non-DAC form does — a difference in kind, not only degree.

What research reports about muscle, body composition, and fat

The evidence that CJC-1295 raises GH and IGF-1 in humans is reasonably solid; the evidence that this translates into measurable lean mass gain is substantially thinner. The foundational human study, published in the Journal of Clinical Endocrinology and Metabolism in 2006, was a dose-escalation trial in healthy adults. It established dose-dependent increases in GH and IGF-1 and characterized the half-life, but it was not designed or powered to measure changes in muscle cross-sectional area or body fat.

What can be said mechanistically is that IGF-1 promotes satellite cell proliferation and activates the PI3K/Akt/mTOR pathway governing muscle protein synthesis, while GH itself promotes lipolysis in adipose tissue by stimulating hormone-sensitive lipase and reducing lipoprotein lipase activity. Studies of GH administration in GH-deficient populations have reported increases in lean mass and reductions in fat mass. Extrapolating those findings to a GHRH analogue in organisms with normal pituitary function is an inference, not a demonstrated result.

Two further points appear consistently in the literature. Anabolic signaling from IGF-1 acts on tissue that is already receiving a mechanical or nutritional stimulus; in sedentary research models, GH-axis elevation alone has produced far more modest changes in lean tissue than in fat mass. And much of the acute weight change reported with GH-axis stimulation reflects fluid retention rather than tissue accretion — an important confounder in any body-composition endpoint. Where investigators have tracked composition shifts, the timeframes discussed run to weeks and months rather than days, and results vary widely with model, diet, and activity.

What research reports about bone density and adult height

CJC-1295 cannot increase adult height, and no peptide can. Longitudinal bone growth occurs at the epiphyseal growth plates, and once those plates fuse — typically in the late teens to early twenties, under the influence of sex steroids — no hormonal signal reopens them. Elevating GH after fusion does not lengthen long bones. In adults with pathological GH excess, the result is acromegaly, characterized by thickening of the hands, feet, and facial bones rather than added height. Any perceived height change in adults comes from posture and spinal decompression, not skeletal elongation.

Bone density is a different endpoint, and here the GH/IGF-1 axis is genuinely relevant. IGF-1 stimulates osteoblast proliferation and collagen synthesis, and GH influences renal 1-alpha-hydroxylase activity and thus calcium handling. Studies of GH administration in deficient adults have reported changes in bone turnover markers and, over longer horizons, in bone mineral density. The catch is that bone remodeling is slow: biochemical markers such as P1NP and CTX can shift within weeks, but densitometric change is generally only resolvable over six to twelve months or more. Direct, controlled studies of CJC-1295 specifically on bone mineral density in humans are not available in the published literature, so any discussion of this endpoint rests on GH-axis physiology rather than compound-specific trial data. IGF-1 is also only one input among many — mechanical loading, vitamin D and calcium status, sex steroids, parathyroid hormone, and age all shape the outcome.

What research reports about combination with ipamorelin and other secretagogues

Pairing a GHRH analogue with a growth hormone secretagogue produces a larger GH release than either alone, and this synergy is the reason CJC-1295 and ipamorelin appear together so often in study designs. The two act through separate receptors: CJC-1295 at the GHRH receptor, ipamorelin at the ghrelin receptor (GHS-R1a). Ghrelin-receptor agonists both stimulate somatotrophs directly and suppress somatostatin, the brake on GH release. Removing the brake while pressing the accelerator yields a supra-additive pulse in published co-administration studies of GHRH plus secretagogue combinations.

Ipamorelin is described as selective because, unlike earlier secretagogues such as GHRP-6 and GHRP-2, it produces minimal stimulation of cortisol and prolactin at comparable GH-releasing doses. That selectivity is the main reason it is favored in research designs where confounding endocrine variables need to be minimized. Either compound can be used alone — a GHRH analogue alone isolates GHRH-receptor signaling, and a secretagogue alone isolates ghrelin-receptor signaling — and single-agent arms are standard controls in synergy experiments.

What research reports about appetite effects

CJC-1295 is not characterized as an appetite stimulant, because GHRH receptors are not the receptors that drive hunger signaling. Appetite stimulation associated with certain secretagogues comes from the ghrelin receptor: ghrelin is the endogenous hunger hormone, and non-selective agonists such as GHRP-6 are well documented to produce pronounced, sometimes intense, increases in food-seeking behavior in both animal and human studies. CJC-1295 does not engage that pathway.

Where appetite changes are observed in GH-axis research, the most plausible explanations are indirect: elevated GH increases lipolysis and metabolic rate, and any sustained increase in energy expenditure can influence feeding behavior. GH also has effects on glucose handling and insulin sensitivity that can influence hunger indirectly. This is a different phenomenon from the acute, receptor-mediated hunger surge produced by ghrelin mimetics. In combination protocols pairing CJC-1295 with ipamorelin, appetite effects are typically reported as minimal, since ipamorelin's selectivity extends to comparatively weak orexigenic activity relative to GHRP-6. The DAC and non-DAC forms do not differ meaningfully on this endpoint, though the sustained metabolic elevation from the DAC form is the more likely of the two to produce indirect effects.

What research reports about safety, tolerability, and purity

Published human data on CJC-1295 are limited to small early-phase studies, and long-term safety in humans has not been established. The 2006 dose-escalation study reported the compound was generally well tolerated in that cohort, with the most commonly noted observations being transient injection-site reactions and facial flushing — the latter consistent with the vasodilatory properties of GHRH analogues generally and typically described as brief. Development of the DAC form was discontinued, and the compound does not hold marketing approval from the FDA or comparable regulators anywhere.

Theoretical concerns discussed in the endocrinology literature for any sustained GH-axis elevation include fluid retention, joint discomfort, carpal tunnel-type symptoms, reduced insulin sensitivity, and — because IGF-1 is mitogenic — questions about the effect of chronic elevation on existing neoplastic tissue. These are extrapolations from GH excess states rather than findings specific to CJC-1295.

Purity is a separate and underappreciated variable. Solid-phase peptide synthesis can leave truncated sequences, deletion analogues, residual solvents, and bacterial endotoxin in the final product. Impurities of this kind are a common source of immunogenic reactions and of irreproducible results, since two vials labeled identically may contain materially different peptide content. Third-party HPLC and mass spectrometry documentation for each lot is the standard way this is verified in research settings.

What research reports about stability, storage, and routes of exposure

Lyophilized CJC-1295 is comparatively stable, while the reconstituted solution is not, and refrigeration requirements differ accordingly. In freeze-dried powder form, the peptide tolerates brief periods at ambient temperature — shipping transit of several days is routine and generally does not compromise integrity — but long-term storage documentation calls for refrigeration, commonly cited at approximately 2 to 8 degrees Celsius, or freezing for extended periods. Once reconstituted with bacteriostatic water, the peptide is in aqueous solution and subject to hydrolysis and aggregation; refrigeration is standard, and stability is generally described in weeks rather than months. Repeated freeze-thaw cycling of reconstituted material is discouraged because ice crystal formation can denature the peptide and cause aggregation. Light exposure and agitation are additional degradation factors.

On routes of exposure: CJC-1295 is not orally active. As a 30-amino-acid peptide, it is cleaved by pepsin in the stomach and by pancreatic proteases in the small intestine into constituent amino acids and short fragments, and even intact peptide of that size crosses the intestinal epithelium poorly. Swallowed material is simply digested as protein. No oral formulation with demonstrated bioavailability exists for this compound. Nasal and transdermal routes face related barriers — nasal delivery of peptides this large achieves only low single-digit bioavailability at best without permeation enhancers, and the stratum corneum is effectively impermeable to molecules of this mass. This is why essentially all published work uses parenteral administration in laboratory settings.

What the regulatory record says about legal status

CJC-1295 is not an approved drug in the United States or other major jurisdictions, and it is not authorized for human consumption; it is sold and shipped as a research chemical for laboratory investigation only. It is also not a controlled substance under the Controlled Substances Act — it is not a steroid and is not scheduled — which is why possession by a research institution is treated differently from possession of a scheduled compound.

The phrase "for research purposes only" is a legal designation with real content. It means the material has not been manufactured under the conditions required for human pharmaceuticals, has not been reviewed for human safety or efficacy by a regulator, and is intended solely for in vitro or in vivo laboratory investigation by qualified personnel. Marketing an unapproved compound with claims about human benefit, or supplying it for human use, falls outside that designation and into misbranding territory under FDA rules. The regulatory picture also varies by country — some jurisdictions classify unapproved peptides more restrictively, and import rules differ.

Separately, CJC-1295 appears on the World Anti-Doping Agency Prohibited List under the category covering growth hormone secretagogues and GHRH analogues, prohibited at all times both in and out of competition. That listing reflects performance-enhancement potential in sport and is independent of national drug law. Anyone evaluating this compound should confirm the current status in their own jurisdiction and institution rather than relying on general summaries.